Atrial Fibrillation Patient Decision Tool

发行商: Leo Lai
评价: 还没有评级
价格: 0.99 USD
兼容性: iPhone & iPad

应用排名历史

查看 中国 中Atrial Fibrillation Patient Decision Tool 的下载量历史排名。
排名历史显示Atrial Fibrillation Patient Decision Tool在iOS应用商店中的流行度以及其随着时间的变化。您可以追踪Atrial Fibrillation Patient Decision Tool在不同国家、分类和设备上每一天每一小时的表现。
下载排名 - iPad - 中国
上周本周
没有上周排名数据
本周数据可在注册后免费使用。
查看本周截至一小时前的数据。

免费注册来发掘更多!

免费注册来获取排名、评价、评级、关键词和更多数据的无限访问权限。

应用说明

The atrial fibrillation patient decision tool is a mobile application created by physicians and pharmacists, designed for patients with atrial fibrillation to choose the most ideal blood thinner agent for their personal preferences and characteristics.

Atrial fibrillation is the most common abnormal heart rhythm in the world. The incidence increases with age. Having atrial fibrillation increases the risk of stroke, which can be quite disabling. To prevent stroke in atrial fibrillation, patients need to take blood thinners. However, there are many agents out there with different characteristics including cost and efficacy. How does a patient who is not well versed in the medical field choose one of these agents? Well, traditionally, it would involve a visit to the doctor’s office and a long conversation. However, we think there is a better way.

This mobile app allows the clinician to take an interactive, educational application to the bedside or exam room of a patient, and show them the decision making process for choosing an appropriate medication for stroke prevention. It allows the patient to visualize the thought process of prioritizing the factors, including cost, complexity, side effect profile, and efficacy. In the end, the app makes a recommendation to the patient, which is based on data from randomized clinical trials that are well accepted in the medical literature.
---------------
Information for health care providers

This electronic tool will aim to standardize the discussion process and take into account the patient's preferences such that the patient is empowered in the decision-making process. A literature review was completed using several landmark trials and consensus guidelines on thromboembolic prophylaxis in patients with atrial fibrillation. For the purposes of assessing the patient's stroke and bleed risk, we reviewed the literature supporting use of the HAS-BLED and CHADS2 scoring systems.

In developing the algorithm, four main factors were considered:
1. Risk of a stroke or thromboembolic event, as determined by the CHADS2 score.
2. Risk of major or minor bleeding, as determined by the HASBLED score.
3. Patient adherence.
4. Cost.

Patients who have renal failure, mechanical heart valves, and various cardiac conditions were excluded from this assessment tool in keeping with the exclusion criteria in the landmark trials.

With clinician assistance, this tool should take less than 15 minutes to complete.

fibrillation decision patient

应用商店优化

人们在寻找一个应用时都使用哪些词?
正确的关键词可以帮助一个应用提高被发现的几率,并且增加下载量和收入。App Annie追踪上百万个关键词,这样您就可以为您的应用获取更多的下载量,并且了解您的竞争对手正在使用哪些关键词。

与 App Annie 一起了解上百万个应用的所有信息,掌握应用行业中正在发生的一切。